Format

Send to

Choose Destination
J Hepatol. 2017 Sep;67(3):585-602. doi: 10.1016/j.jhep.2017.03.006. Epub 2017 Mar 18.

ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients.

Author information

1
Department of Hepatology and Gastroenterology, Niguarda Hospital, Italy; International Centre for Digestive Health, School of Medicine and Surgery, University of Milano Bicocca, Italy. Electronic address: luca.belli@ospedaleniguarda.it.
2
Department of Hepatology and Liver Transplant Unit, Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Est University, Creteil, France.
3
Hepatology& Liver Transplantation Unit, Hospital Universitari I Politècnic La Fe, University of Valencia & Ciberhed, Valencia, Spain.
4
Section of Hepatology, Clinic for Gastroenterology and Rheumatology, University Clinic Leipzig, Germany.
5
Centre Hepato-Biliaire,Paul Brousse Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Sud University, Villejuif, France.
6
Hepatology and Gastroenterology, Unversity of Gent, Belgium.
7
Gastroenterology and Transplant Hepatology, Papa Giovanni XXIII Hospital, Bergamo, Italy.
8
Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool.
9
Department of Hepatology, Gastroenterology, and Liver Transplantation, Centre Hospitalier Universitaire, Saint Eloi, Montpellier, France.
10
Department of Infective Diseases. Niguarda Hospital, Milan, Italy.
11
International Centre for Digestive Health, School of Medicine and Surgery, University of Milano Bicocca, Italy; Yale University Liver Center, Department of Medicine New Haven, USA.

Abstract

The advent of safe and highly effective direct-acting antiviral agents (DAAs) has had huge implications for the hepatitis C virus (HCV) transplant field, and changed our management of both patients on the waiting list and those with HCV graft re-infection after liver transplantation (LT). When treating HCV infection before LT, HCV re-infection of the graft can be prevented in nearly all patients. In addition, some candidates show a remarkable clinical improvement and may be delisted. Alternatively, HCV infection can be treated post-LT either soon after the transplant, taking advantage of the removal of the infected native liver, or at the time of disease recurrence, as was carried out in the past. In either case, some DAAs have a limited use because of their drug to drug interactions with various immunosuppressants as well as the many other drugs liver transplant recipients are often prescribed. In addition, some DAAs should be avoided in case of severe renal failure, which is not an unusual complication after LT. The present document provides a series of consensus statements on the LT issues that have not been extensively addressed previously. These statements have been developed to support physicians and other stakeholders in charge of LT candidates and recipients when deciding to treat HCV, especially in difficult situations.

KEYWORDS:

Antiviral agents; Guidelines; Hepatitis C, chronic; Interferons; Liver failure; Liver transplant candidate; Liver transplant recipient; Liver transplantation; Recurrent hepatitis C; Waiting lists

PMID:
28323126
DOI:
10.1016/j.jhep.2017.03.006
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center